Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Sara A. Hurvitz, MD, on the DESTINY-Breast03 Trial: T-DXd Versus T-DM1 for HER2+ Breast Cancer

Posted: Tuesday, March 15, 2022

Sara A. Hurvitz, MD, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, interprets the clinical implications of phase III findings from the DESTINY-Breast03 trial, which favored the use of ado-trastuzumab deruxtecan (T-DXd) over standard-of-care trastuzumab emtansine (T-DM1) for patients with HER2-positive metastatic breast cancer. In addition to the efficacy data, Dr. Hurvitz examines safety differences between the regimens.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.